E. Ohman J:Or Asset Management Ab Bristol Myers Squibb CO Transaction History

E. Ohman J:Or Asset Management Ab

$3.76 Trillion
Q1 2025

A detailed history of E. Ohman J:Or Asset Management Ab transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, E. Ohman J:Or Asset Management Ab holds 26,512 shares of BMY stock, worth $1.32 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

26,512

Previous 30,000 11.63%

Holding current value

$1.32 Million

Previous $1.7 Billion 4.7%

% of portfolio

0.04%

Previous 0.04%

58 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 Apr 11, 2025	SELL	$53.9 - $63.11 $188,003 - $220,127	-3,488 Reduced 11.63%	26,512 $1.62 Billion
Q3 2024 Oct 23, 2024	SELL	$39.66 - $51.75 $206,231 - $269,100	-5,200 Reduced 14.77%	30,000 $1.55 Billion
Q4 2023 Feb 15, 2024	BUY	$48.48 - $57.85 $1.71 Million - $2.04 Million	35,200 New	35,200 $1.81 Billion
Q2 2023 Apr 05, 2024	SELL	$63.71 - $70.74 $6.1 Million - $6.78 Million	-95,800 Closed	0 $0
Q1 2023 Apr 05, 2024	BUY	$65.71 - $74.53 $282,553 - $320,479	4,300 Added 4.7%	95,800 $6.64 Billion
Q4 2022 Apr 05, 2024	SELL	$68.48 - $81.09 $82,176 - $97,308	-1,200 Reduced 1.29%	91,500 $6.58 Billion
Q3 2022 Apr 05, 2024	SELL	$0.13 - $76.84 $533 - $315,044	-4,100 Reduced 4.24%	92,700 $6.59 Billion
Q2 2022 Apr 05, 2024	SELL	$72.62 - $79.98 $283,218 - $311,922	-3,900 Reduced 3.87%	96,800 $7.45 Billion
Q1 2022 Apr 05, 2024	SELL	$61.48 - $73.72 $577,912 - $692,968	-9,400 Reduced 8.54%	100,700 $7.35 Billion
Q4 2021 Apr 05, 2024	BUY	$53.63 - $62.52 $573,841 - $668,964	10,700 Added 10.76%	110,100 $6.86 Billion
Q3 2021 Apr 05, 2024	BUY	$59.17 - $69.31 $118,340 - $138,620	2,000 Added 2.05%	99,400 $5.88 Billion
Q2 2021 Apr 05, 2024	BUY	$61.91 - $67.42 $526,235 - $573,070	8,500 Added 9.56%	97,400 $6.51 Billion
Q1 2021 Apr 05, 2024	BUY	$59.34 - $66.74 $2.55 Million - $2.87 Million	43,000 Added 93.68%	88,900 $5.61 Billion
Q4 2020 Apr 05, 2024	SELL	$57.74 - $65.43 $207,864 - $235,548	-3,600 Reduced 7.27%	45,900 $2.85 Billion
Q3 2020 Apr 05, 2024	SELL	$57.43 - $63.64 $2.06 Million - $2.28 Million	-35,900 Reduced 42.04%	49,500 $2.98 Billion
Q2 2020 Apr 05, 2024	BUY	$54.82 - $64.09 $82,230 - $96,135	1,500 Added 1.79%	85,400 $5.02 Billion
Q1 2020 Apr 05, 2024	SELL	$46.4 - $67.43 $1.5 Million - $2.18 Million	-32,300 Reduced 27.8%	83,900 $4.68 Billion
Q4 2019 Apr 05, 2024	BUY	$49.21 - $64.19 $2.18 Million - $2.84 Million	44,300 Added 61.61%	116,200 $7.46 Billion
Q3 2019 Apr 05, 2024	BUY	$42.77 - $50.71 $128,310 - $152,130	3,000 Added 4.35%	71,900 $3.65 Billion
Q2 2019 Apr 05, 2024	BUY	$44.62 - $49.34 $111,550 - $123,350	2,500 Added 3.77%	68,900 $3.12 Billion
Q1 2019 Apr 05, 2024	SELL	$45.12 - $53.8 $15.8 Million - $18.9 Million	-350,700 Reduced 84.08%	66,400 $3.17 Billion
Q4 2018 Apr 05, 2024	BUY	$48.76 - $63.23 $5.48 Million - $7.11 Million	112,377 Added 36.88%	417,100 $21.7 Billion
Q3 2018 Apr 05, 2024	BUY	$55.19 - $62.25 $12.9 Million - $14.6 Million	233,923 Added 330.4%	304,723 $18.9 Billion
Q2 2018 Apr 05, 2024	BUY	$50.53 - $62.98 $1.19 Million - $1.49 Million	23,600 Added 50.0%	70,800 $3.92 Billion
Q1 2018 Apr 05, 2024	SELL	$59.92 - $68.98 $89,880 - $103,470	-1,500 Reduced 3.08%	47,200 $2.99 Billion
Q4 2017 Apr 05, 2024	BUY	$59.94 - $65.35 $215,784 - $235,259	3,600 Added 7.98%	48,700 $2.98 Billion
Q3 2017 Apr 05, 2024	BUY	$55.23 - $63.74 $49,707 - $57,366	900 Added 2.04%	45,100 $2.87 Billion
Q1 2017 Apr 05, 2024	BUY	N/A	4,900 Added 12.47%	44,200 $2.4 Billion
Q4 2016 Apr 05, 2024	BUY	N/A	3,800 Added 10.7%	39,300 $2.3 Billion
Q3 2016 Apr 05, 2024	BUY	N/A	3,400 Added 10.59%	35,500 $1.91 Billion
Q2 2016 Apr 05, 2024	BUY	N/A	1,600 Added 5.25%	32,100 $2.36 Billion
Q1 2016 Apr 05, 2024	SELL	N/A	-2,300 Reduced 7.01%	30,500 $1.95 Billion
Q4 2015 Apr 05, 2024	BUY	N/A	2,200 Added 7.19%	32,800 $2.26 Billion
Q3 2015 Apr 05, 2024	SELL	N/A	-4,700 Reduced 13.31%	30,600 $1.81 Billion
Q2 2015 Apr 05, 2024	SELL	N/A	-2,000 Reduced 5.36%	35,300 $2.35 Billion
Q1 2015 Apr 05, 2024	BUY	N/A	2,700 Added 7.8%	37,300 $2.41 Billion
Q4 2014 Apr 05, 2024	SELL	N/A	-2,400 Reduced 6.49%	34,600 $2.05 Billion
Q2 2014 Apr 05, 2024	SELL	N/A	-2,600 Reduced 6.57%	37,000 $1.79 Billion
Q1 2014 Apr 05, 2024	SELL	N/A	-2,000 Reduced 4.81%	39,600 $2.06 Billion
Q4 2013 Apr 05, 2024	SELL	N/A	-200 Reduced 0.48%	41,600 $2.22 Billion
Q3 2013 Apr 05, 2024	BUY	N/A	2,300 Added 5.82%	41,800 $1.93 Billion
Q2 2013 Apr 05, 2024	SELL	N/A	-6,400 Reduced 13.94%	39,500 $1.77 Billion
Q1 2013 Apr 05, 2024	BUY	N/A	2,400 Added 5.52%	45,900 $1.89 Billion
Q3 2012 Apr 05, 2024	BUY	N/A	1,600 Added 3.82%	43,500 $1.47 Billion
Q2 2012 Apr 05, 2024	SELL	N/A	-5,900 Reduced 12.34%	41,900 $1.51 Billion
Q1 2012 Apr 05, 2024	BUY	N/A	14,000 Added 41.42%	47,800 $1.61 Billion
Q4 2011 Apr 05, 2024	BUY	N/A	1,500 Added 4.64%	33,800 $1.19 Billion
Q3 2011 Apr 05, 2024	SELL	N/A	-4,400 Reduced 11.99%	32,300 $1.01 Billion
Q2 2011 Apr 05, 2024	BUY	N/A	2,600 Added 7.62%	36,700 $1.06 Billion
Q1 2011 Apr 05, 2024	BUY	N/A	4,000 Added 13.29%	34,100 $908 Million
Q2 2010 Apr 05, 2024	BUY	N/A	4,259 Added 16.48%	30,100 $751 Million
Q4 2009 Apr 05, 2024	SELL	N/A	-8,259 Reduced 24.22%	25,841 $652 Million
Q2 2009 Apr 05, 2024	BUY	N/A	6,800 Added 24.91%	34,100 $693 Million
Q4 2008 Apr 05, 2024	BUY	N/A	5,600 Added 25.81%	27,300 $635 Million
Q3 2008 Apr 05, 2024	SELL	N/A	-5,800 Reduced 21.09%	21,700 $452 Million
Q2 2008 Apr 05, 2024	BUY	N/A	8,500 Added 44.74%	27,500 $565 Million
Q4 2007 Apr 05, 2024	BUY	N/A	2,600 Added 15.85%	19,000 $504 Million
Q4 2006 Apr 05, 2024	SELL	N/A	-18,800	16,400 $432 Million

Others Institutions Holding BMY

# of Institutions

2,779

Shares Held

1.56B

Call Options Held

28M

Put Options Held

28.7M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $106B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of E. Ohman J:Or Asset Management Ab, based on Form 13F filings with the SEC.

News

Stay updated on E. Ohman J:Or Asset Management Ab with notifications on news.

Account

E. Ohman J:Or Asset Management Ab Bristol Myers Squibb CO Transaction History